Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Daryl K A ChiaRaghav SundarGuowei KimJia Jun AngJeffrey H Y LumMin En NgaGiap Hean GohJu Ee SeetCheng Ean CheeHon Lyn TanJingshan HoNatalie Y L NgoiMatilda X W LeeVaishnavi MuthuGloria H J ChanAngela S L PangYvonne L E AngJoan R E ChooJoline S J LimJun Liang TehAung LwinYuen SoonAsim ShabbirJimmy Bok-Yan SoWei Peng YongPublished in: Annals of surgical oncology (2022)
IP PTX with XELOX is a promising treatment option for GCPM patients. In patients with good response, conversion surgery was feasible with favourable outcomes.
Keyphrases
- phase ii study
- end stage renal disease
- locally advanced
- open label
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- randomized controlled trial
- clinical trial
- radiation therapy
- rectal cancer
- coronary artery disease
- combination therapy
- study protocol
- adipose tissue
- replacement therapy
- percutaneous coronary intervention
- metastatic breast cancer